Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation
- 6 August 2018
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 72 (7), 721-733
- https://doi.org/10.1016/j.jacc.2018.05.058
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- Regulation and Prognostic Relevance of Symmetric Dimethylarginine Serum Concentrations in Critical Illness and SepsisMediators of Inflammation, 2013
- Assessment of Endothelial Dysfunction: The Role of Symmetrical Dimethylarginine and Proinflammatory Markers in Chronic Kidney Disease and Renal Transplant RecipientsDisease Markers, 2013
- Mechanism of Cellular Oxidation Stress Induced by Asymmetric DimethylarginineInternational Journal of Molecular Sciences, 2012
- Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Improving Stroke Risk Stratification Using the CHADS 2 and CHA 2 DS 2 -VASc Risk Scores in Patients With Paroxysmal Atrial Fibrillation by Continuous Arrhythmia Burden MonitoringStroke, 2011
- The role of asymmetric and symmetric dimethylarginines in renal diseaseNature Reviews Nephrology, 2011
- Myeloperoxidase acts as a profibrotic mediator of atrial fibrillationNature Medicine, 2010
- Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 1321 Patients With Nonvalvular Atrial FibrillationCirculation, 2002
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991